Jonas JB, Kamppeter BA, Harder B, et al. 2006. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther, 22:200–7. Jonas JB, Kreissig I, Spandau UH, et al. 2006. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol, 141:579–80. Jonas JB, Neumaier M. 2007. Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy. Clin Experiment Ophthalmol, 35:186–7. Kaderli B, Avci R, Gelisken O, et al. 2005. Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopa- thy and diffuse diabetic macular oedema. Combined IVTA and laser treatment for PDR with CSMO. Int Ophthalmol, 26:207–14. Katsura Y, Okano T, Matsuno K, et al. 2005. Erythropoietin is highly elevated in vitreous ﬂuid of patients with proliferative diabetic reti- nopathy. Diabetes Care, 28:2252–4. Klein R, Klein BE, Moss SE, et al. 1984a. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic reti- nopathy when age at diagnosis is 30 or more years. Arch Ophthalmol, 102:527–32. Klein R, Klein BE, Moss SE, et al. 1984b. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic reti- nopathy when age at diagnosis is less than 30 years. Arch Ophthalmol, 102:520–6. Klein R, Klein BE, Moss SE, et al. 1988. Glycosylated hemoglobin pre- dicts the incidence and progression of diabetic retinopathy. JAMA, 260:2864–71. Klein BE, Moss SE, Klein R, et al. 1991. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology, 98:1261–5. Kociok N, Krohne TU, Poulaki V, et al. 2007. Geldanamycin treatment reduces neovascularization in a mouse model of retinopathy of prema- turity. Graefes Arch Clin Exp Ophthalmol, 245:258–66. Konner J, Dupont J. 2004. Use of soluble recombinant decoy receptor vas- cular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer, 4(Suppl 2):S81–5. Krepler K, Biowski R, Schrey S, et al. 2002. Cataract surgery in patients with diabetic retinopathy: visual outcome, progression of diabetic retinopathy, and incidence of diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol, 240:735–738. Krzystolik MG, Filippopoulos T, Ducharme JF, et al. 2006. Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy. Arch Ophthalmol, 124:920–1. Kunisaki M, Bursell SE, Clermont AC, et al. 1995. Vitamin E prevents diabetes-induced abnormal retinal blood ﬂow via the diacylglycerol- protein kinase C pathway. Am J Physiol, 269:E239–46. Kuppermann BD, Thomas EL, de Smet MD, et al. 2005. Pooled efﬁcacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly puriﬁed ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthal- mol, 140:573–84. Kuppermann BD, Blumenkranz MS, Haller JA, et al. 2007. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol, 125:309–17. Lam DS, Chan CK, Mohamed S, et al. 2007. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema six-month outcomes. Ophthalmology, Apr 23; [Epub ahead of print] Diabetic retinopathy Lewis H, Abrams GW, Blumenkranz MS, Campo RV. 1992. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology, 99:753–9. Lyons TJ, Jenkins AJ, Zheng D, et al. 2004. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci, 45:910–18. Mason JO 3rd, Colagross CT, Vail R. 2006. Diabetic vitrectomy: risks, prognosis, future trends. Curr Opin Ophthalmol, 17:281–5. Miyamoto N, Iossifov D, Metge F, et al. 2006. Early effects of intravitreal triamcinolone on macular edema: mechanistic implication. Ophthal- mology, 113:2048–53. Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. 1988. The role of the vitreous in diabetic macular edema. Ophthalmology, 95:1335–9. Nasrallah FP, Van de Velde F, Jalkh AE, et al. 1989. Importance of the vitreous in young diabetics with macular edema. Ophthalmology, 96:1511–16. Nauck M, Karakiulakis G, Perruchoud AP, et al. 1998. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol, 341:309–15. Robinson WGJ, Kador PF, Kinoshita JH. 1983. Retinal capillaries: base- ment membrance thickening by galactosemia preventede with aldose reductase inhibitor. Science, 221:1177–9. Sen K, Misra A, Kumar A, et al. 2002. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract, 56:1–11. Suto C, Hori S, Kato S, et al. 2006. Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol, 124:38–45. Suzuma K, Takahara N, Suzuma I, et al. 2002. Characterization of protein kinase C beta isoform’s action on retinoblastoma protein phosphory- lation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A, 99:721–6. Uhlmann K, Kovacs P, Boettcher Y, et al. 2006. Genetics of diabetic reti- nopathy. Exp Clin Endocrinol Diabetes, 114:275–94. van der Pijl JW, Lemkes HH, Frolich M, et al. 1999. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. J Am Soc Nephrol, 10:1331–6. van Leiden HA, Dekker JM, Moll AC, et al. 2002. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care, 25:1320–5. Watanabe D, Suzuma K, Matsui S, et al. 2005. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med, 353:782–92. Wilkinson-Berka JL, Wraight C, Werther G. 2006. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic reti- nopathy. Curr Med Chem, 13:3307–17. Xu X, Zhu Q, Xia X, et al. 2004. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res, 28:251–6. Yamamoto T, Akabane N, Takeuchi S. 2001. Vitrectomy for diabetic macu- lar edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol, 132:369–77. Zein, WM, Noureddin BN, Jurdi FA, et al. 2006. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of prolif- erative diabetic retinopathy with macular edema. Retina, 26:137–42. Clinical Ophthalmology 2008:2(2) 433